Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) FCF Margin (2020 - 2025)

Historic FCF Margin for Barinthus Biotherapeutics (BRNS) over the last 6 years, with Q2 2025 value amounting to 1814100.0%.

  • Barinthus Biotherapeutics' FCF Margin changed N/A to 1814100.0% in Q2 2025 from the same period last year, while for Sep 2025 it was 9768.45%, marking a year-over-year decrease of 93536600.0%. This contributed to the annual value of 199.29% for FY2024, which is 68254000.0% up from last year.
  • As of Q2 2025, Barinthus Biotherapeutics' FCF Margin stood at 1814100.0%.
  • Over the past 5 years, Barinthus Biotherapeutics' FCF Margin peaked at 839600.0% during Q4 2021, and registered a low of 1814100.0% during Q2 2025.
  • Moreover, its 5-year median value for FCF Margin was 1213.89% (2023), whereas its average is 80324.83%.
  • Per our database at Business Quant, Barinthus Biotherapeutics' FCF Margin skyrocketed by 2000000000bps in 2021 and then tumbled by 2000000000bps in 2022.
  • Quarter analysis of 5 years shows Barinthus Biotherapeutics' FCF Margin stood at 839600.0% in 2021, then crashed by -100bps to 184.75% in 2022, then plummeted by -3138bps to 5982.04% in 2023, then surged by 98bps to 122.33% in 2024, then plummeted by -1482822bps to 1814100.0% in 2025.
  • Its last three reported values are 1814100.0% in Q2 2025, 4717.41% for Q1 2025, and 122.33% during Q3 2024.